Peterlin P, Gaschet J, Turlure P, Gourin M-P, Dumas P-Y, Thepot S, Berceanu A, Park S, Hospital M-A, Cluzeau T, Torregrosa-Diaz J-M, Drevon L, Sapena R, Chermat F, Ades L, Dimicoli-Salazar S, Jullien M, Fenaux P, Chevallier. P. FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. Haematologica; https://doi.org/10.3324/haematol.2024.286025 [Early view].